Welcome to our dedicated page for Nrx Pharmaceuticals SEC filings (Ticker: NRXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. NRx Pharmaceuticals is a Delaware-incorporated, clinical-stage biopharmaceutical company focused on NMDA-based therapies for central nervous system disorders, including suicidal depression, bipolar depression, chronic pain, and PTSD. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols NRXP and NRXPW, respectively, as reflected in multiple Form 8-K filings.
Through this page, readers can review Form 10-Q and related notifications such as Form 12b-25 (NT 10-Q), which explain timing of quarterly report submissions and provide context on financial reporting. Form 8-K filings document material events, including registered direct offerings of common stock, acquisitions and strategic interests executed through the HOPE Therapeutics subsidiary, changes in independent registered public accounting firms, and FDA-related developments that the company chooses to disclose under Regulation FD or Item 8.01 Other Events.
For a company like NRx Pharmaceuticals, which is advancing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), SEC filings can shed light on capital-raising activities, use of at-the-market offering programs, and the financial impact of building an interventional psychiatry clinic network. Filings related to acquisitions, such as Dura Medical, LLC and Cohen & Associates, include pro forma financial information and audited or unaudited financial statements that help illustrate how these clinic operations integrate into the consolidated company.
Stock Titan enhances access to these documents with real-time updates from EDGAR and AI-powered summaries that explain the key points of each filing in clear language. Users can quickly understand the significance of 8-K disclosures, accounting firm changes, and other regulatory items without reading every technical detail. This structure allows investors to monitor NRXP’s evolving financial condition, corporate transactions, and governance disclosures directly from its official SEC record.
NRX Pharmaceuticals has formally requested the withdrawal of its Form S-1 Registration Statement (File No. 333-283220) that was initially filed on November 14, 2024. The company has decided not to proceed with its planned public offering at this time.
Key points:
- The withdrawal request was made pursuant to Rule 477(a) under the Securities Act of 1933
- The Registration Statement had not been declared effective by the SEC
- No securities were sold under this Registration Statement
- The request was signed by Jonathan Javitt, Chairman and Interim Chief Executive Officer
This withdrawal could signal a shift in the company's capital raising strategy or a response to market conditions. The decision to withdraw rather than proceed with the public offering may have implications for the company's growth plans and funding options.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission dated June 20, 2025. The filing enables the company to issue up to $150 million worth of securities—including common stock, preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts and units—on a continuous or delayed basis under Rule 415.
The company is classified as a non-accelerated filer and smaller reporting company, indicating market capitalization under SEC thresholds. Its common stock last traded at $3.23 per share on June 18, 2025.
Under Rule 415(a)(6), the registration statement carries forward $90,592,307 of unsold securities from the prior shelf registration (File No. 333-265492, declared effective June 21, 2022). The associated filing fee of $8,397.91 is likewise carried forward. Once the new registration becomes effective, the prior shelf will be deemed terminated for the remaining unsold amount. Should any of these securities be sold before effectiveness, NRXP will file a pre-effective amendment to reconcile the balances.
NRx may sell securities through agents, underwriters, dealers or directly to investors; specific terms, pricing and net proceeds will be detailed in subsequent prospectus supplements or free-writing prospectuses. Investors are directed to the prospectus’ “Risk Factors” section and other incorporated documents for a full discussion of uncertainties related to the offering.
The flexibility afforded by the shelf facility provides NRXP with a mechanism to raise capital expediently as corporate needs arise, but it also introduces potential dilution and leverage considerations for existing shareholders.